Skip to main content
. Author manuscript; available in PMC: 2020 Dec 12.
Published in final edited form as: Antivir Ther. 2010;15(7):935–950. doi: 10.3851/IMP1667

Figure 5.

Figure 5.

Metabolic activation and antiviral activity of SATE monophosphate prodrugs

aEffective concentration of compound required to reduce HCV replication by 50% (EC50). bConcentration of inhibitor reducing cell viability by 50% (CC50). cParent nucleoside (Nuc). C, cytosine; SATE, S-acyl-2-thioethyl; t-Bu, tert-butyl; U, uracil.